Top

Published in:

01-06-2018 | Original Article

Palivizumab use in infants with Down syndrome—report from the German Synagis™ Registry 2009–2016

Authors: Arne Simon, Susanne Gehrmann, Gudrun Wagenpfeil, Stefan Wagenpfeil

Published in: European Journal of Pediatrics | Issue 6/2018

Abstract

Infants with Down syndrome (DS) face an increased risk of respiratory tract infections. Recent studies describe DS as independent risk factor for a complicated clinical course in infants with respiratory syncytial virus (RSV) infection. The prospective observational German Synagis™ Registry comprises data from 249 children below 25 months of age with DS and palivizumab prophylaxis 2009–2016 (1191 administrations; mean 4.8 per patient and season). The median gestational age and the birth weight in patients without and with DS were 31 versus 37 weeks (P < 0.001) and 1590 versus 2750 g, respectively (P < 0.001). Patients with DS significantly more often had congenital heart disease (CHD), siblings in kindergarten or school, treatment with oxygen at home, immunodeficiency, and neuromuscular impairment. The RSV-related hospitalization rate in patients with DS was 1.20%; the hospitalization rate in patients without DS was 0.71%.

Conclusion: Data from 249 children with DS receiving palivizumab prophylaxis in seven consecutive RSV seasons (2009–2016) in Germany reveal important differences between patients with and without DS concerning the main indication for palivizumab use and additional risk factors. Bearing in mind the limitations of an uncontrolled postmarketing observational study, the results confirm the field effectiveness of palivizumab prophylaxis in this special population.

What is Known:

• Recent studies describe the Down syndrome as independent risk factor for a complicated clinical course in infants with RSV infection.

What is New:

• Compared with other infants receiving palivizumab prophylaxis, patients with Down syndrome significantly more often had congenital heart disease, siblings in kindergarten or school, treatment with oxygen at home, immunodeficiency, and neuromuscular impairment.

• In infants with palivizumab prophylaxis breakthrough, RSV-related hospitalization rates were not significantly higher in those with Down syndrome.

Synagis®; formerly licensed by Abbot Laboratories Limited, UK, now licensed by Medimmune/AbbVie®).

Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ (2007) Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis—a prospective birth-cohort study. Pediatrics 120(4):e1076–e1081. https://doi.org/10.1542/peds.2007-0788 CrossRefPubMed

Boghossian NS, Hansen NI, Bell EF, Stoll BJ, Murray JC, Laptook AR, Shankaran S, Walsh MC, Das A, Higgins RD (2010) Survival and morbidity outcomes for very low birth weight infants with Down syndrome. Pediatrics 126(6):1132–1140. https://doi.org/10.1542/peds.2010-1824 CrossRefPubMedPubMedCentral

Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctot KL (2015) Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J 34(12):e290–e297. https://doi.org/10.1097/inf.0000000000000922 CrossRefPubMed

Deutsche Gesellschaft für Pädiatrische Infektiologie (DGPI), Deutsche Gesellschaft für Pädiatrische Kardiologie (DGPK), Deutsche Gesellschaft für Pädiatrische Pneumonologie (DPP), Deutsche Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI) (2008) Stellungnahme zur Prophylaxe von schweren RSV-Erkrankungen bei Risikokindern mit Palivizumab. http://wwwdgpide/pdf/Palivizumab_LL_final_30Sep2008pdf (30. September 2008)

Deutsche Gesellschaft für Pädiatrische Infektiologie (DGPI), Deutsche Gesellschaft für Pädiatrische Kardiologie (DGPK), Gesellschaft für Pädiatrische Pneumologie (GPP), Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI), Berufsverband der Kinder- und Jugendärzte (BVKJ), Bundesverband „Das frühgeborene Kind“ e.V. (2012) AWMF-LL 048-012 - Leitlinie zur Prophylaxe von schweren Erkrankungen durch Respiratory Syncytial Virus (RSV) bei Risikokindern 28. Oktober2012

Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143(4):532–540CrossRefPubMed

Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360(6):588–598. https://doi.org/10.1056/NEJMoa0804877 CrossRefPubMedPubMedCentral

Kabbani MS, Giridhar S, Elbarbary M, Elgamal MA, Najm H, Godman M (2005) Postoperative cardiac intensive care outcome for Down syndrome children. Saudi Med J 26(6):943–946PubMed

Kristensen K, Hjuler T, Ravn H, Simoes EA, Stensballe LG (2012) Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 54(6):810–817. https://doi.org/10.1093/cid/cir928 CrossRefPubMed

10.

Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, Svendsen AL, Nielsen BW (2009) Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 94(10):785–789. https://doi.org/10.1136/adc.2008.143057 CrossRefPubMed

11.

Medrano Lopez C, Garcia-Guereta Silva L, Lirio Casero J, Garcia Perez J (2009) Respiratory infections, Down’s syndrome and congenital heart disease: the CIVIC 21 study. An Pediatr (Barc) 71(1):38–46. https://doi.org/10.1016/j.anpedi.2008.11.007 CrossRef

12.

Megged O, Schlesinger Y (2010) Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J 29(7):672–673. https://doi.org/10.1097/INF.0b013e3181d7ffa5 CrossRefPubMed

13.

Paes B, Manzoni P (2011) Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Hum Dev 87(Suppl 1):S55–S58. https://doi.org/10.1016/j.earlhumdev.2011.01.012 CrossRefPubMed

14.

PaesB, MitchellI, LiA, HarimotoT, LanctotKL (2013) Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol2013:917068. doi:https://doi.org/10.1155/2013/917068, 1, 15

15.

Paes B, Mitchell I, Li A, Lanctot KL (2012) A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis 31(10):2703–2711. https://doi.org/10.1007/s10096-012-1617-7 [doi]

16.

Paes B, Mitchell I, Li A, Lanctot KL (2012) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatrin press. https://doi.org/10.1007/s00431-011-1654-8 [doi]

17.

Paes B, Mitchell I, Li A, Lanctot KL (2012) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 171(5):833–841. https://doi.org/10.1007/s00431-011-1654-8 [doi]

18.

Paes B, Mitchell I, Yi H, Li A, Lanctot KL (2014) Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J 33(2):e29–e33. https://doi.org/10.1097/inf.0000000000000019 CrossRefPubMed

19.

Perez-Padilla R, Fernandez R, Garcia-Sancho C, Franco-Marina F, Aburto O, Lopez-Gatell H, Bojorquez I (2010) Pandemic (H1N1) 2009 virus and Down syndrome patients. Emerg Infect Dis 16(8):1312–1314. https://doi.org/10.3201/eid1608.091931 [doi]

20.

Sanchez-Luna M, Medrano C, Lirio J (2016) Down syndrome as risk factor for respiratory syncytial virus hospitalization: a prospective multicenter epidemiological study. Influenza Other Respir Viruses 11:157–164. https://doi.org/10.1111/irv.12431 CrossRefPubMedPubMedCentral

21.

Simon A, Nowak H, Sterz R (2011) Use of Palivizumab in Germany: data from 2002–2007. Klin Padiatr 223(5):292–298. https://doi.org/10.1055/s-0030-1270515 [doi]

22.

Simon A, Volz S, Fleischhack G, Tillman R, Muller A, Bode U, Schildgen O (2007) Human coronavirus OC43 pneumonia in a pediatric cancer patient with down syndrome and acute lymphoblastic leukemia. J Pediatr Hematol Oncol 29(6):432–434CrossRefPubMed

23.

Stagliano DR, Nylund CM, Eide MB, Eberly MD (2015) Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. J Pediatr 166(3):703–709e702. https://doi.org/10.1016/j.jpeds.2014.11.058 CrossRefPubMed

24.

Sullivan C, Morgan C (2014) PC.74 The importance of testing for Respiratory Syncytial Virus (RSV) in infants presenting with bronchiolitis who are receiving palivizumab. Arch Dis Child Fetal Neonatal Ed 99(Suppl 1):A61.3–A6A61. https://doi.org/10.1136/archdischild-2014-306576.175 CrossRef

25.

The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3 Pt 1):531–537CrossRef

26.

Whelan B, Musters E, Murray A, Moore E, Lievaart L, Visser S, Toxopeus E, van Veen A, Notario G, Campbell FJ (2016) Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. Drugs Therapy Perspectives: Rational Drug Selection Use 32:119–130. https://doi.org/10.1007/s40267-015-0275-0 CrossRef

27.

Yi H, Lanctot KL, Bont L, Bloemers BL, Weijerman M, Broers C, Li A, Kiss A, Mitchell I, Paes B (2014) Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics 133(6):1031–1037. https://doi.org/10.1542/peds.2013-3916 CrossRefPubMed

28.

Zachariah P, Ruttenber M, Simoes EA (2011) Hospitalization due to respiratory syncytial virus in children with congenital malformations. Pediatr Infect Dis J 30(5):442–445. https://doi.org/10.1097/INF.0b013e318201813b [doi]

29.

Zachariah P, Ruttenber M, Simoes EA (2012) Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr 160(5):827–831. https://doi.org/10.1016/j.jpeds.2011.11.004 CrossRefPubMed

Title: Palivizumab use in infants with Down syndrome—report from the German Synagis™ Registry 2009–2016
Authors: Arne Simon
Susanne Gehrmann
Gudrun Wagenpfeil
Stefan Wagenpfeil
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 6/2018
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-018-3142-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Palivizumab use in infants with Down syndrome—report from the German Synagis™ Registry 2009–2016

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Clinical profile and outcome of children with scrub typhus from Chennai, South India

Sleep duration, body composition, dietary profile and eating behaviours among children and adolescents: a comparison between Portuguese acrobatic gymnasts

Dutch guideline for clinical foetal-neonatal and paediatric post-mortem radiology, including a review of literature

Diagnostic characteristics of anterior cutaneous nerve entrapment syndrome in childhood

Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle

The impact of coping patterns and chronic health conditions on health-related quality of life among children and adolescents